On Friday, Doximity got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.
The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
Doximity is now out of buy range after breaking out from a 30.50 entry in a cup with handle.
Lean How — And When — To Sell Stocks
The stock earns a 99 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth is outpacing 99% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company reported 36% earnings growth for Q2. Top line growth increased 20%, up from 17% in the prior quarter. That marks two quarters of rising growth.
Doximity holds the No. 1 rank among its peers in the Computer Software-Medical industry group. Veeva Systems Cl A and Waystar Holding are also among the group's highest-rated stocks.
